Revenio Group Oyj - Inside information

Revenio Group Corporation announces intention to offer shares to institutional investors

REVENIO GROUP CORPORATION: Stock exchange release

Insider information 24 APRIL 2019, at 18:30 EET

Not for release, publication or distribution, directly or indirectly, in or into
the United States, Australia, Canada, New Zealand, Singapore, Hong Kong or Japan
or in any other jurisdiction in which publication or distribution would be
prohibited by applicable law.
Revenio announces intention to offer shares to institutional investors

Revenio Group Corporation ("Revenio" or "Company") intends to offer up to
2,350,000 new shares in the Company ("Shares") to a limited number of
institutional investors in a directed share issue in deviation from the
shareholders’ pre-emptive rights (“Offering”). The maximum number of Shares
offered in the Offering corresponds to approximately 9.8 per cent of all of the
shares and votes of the Company immediately prior to the Offering. The Offering
is carried out on the basis of the authorisation granted to the Board of
Directors by the Annual General Meeting 20 March 2018. The Company has a weighty
financial reason for deviating from the pre-emptive subscription right of the
shareholders. The Company intends to use the proceeds from the Offering to
finance the acquisition of CenterVue SpA announced on 13 April 2019, to support
the Company’s growth strategy, optimise the capital structure of the Company,
and to expand the Company’s shareholder base and thus enhance the liquidity of
the Company’s share.

The Offering will be carried out subject to the fulfilment of certain terms,
organised by Carnegie Investment Bank AB and Danske Bank A/S, Finland Branch, in
an accelerated book-building process in which selected institutional investors
may submit bids for the Shares. The share subscription and sale price of the
Shares will be determined by the bids received in the accelerated book-building
process. The book-building will commence immediately and is expected to end by
9:00 EET on 25 April 2019 at the latest. Book-building can be discontinued at
any time during the book-building process. After the close of the book-building
process, the Board of Directors of Revenio shall make the decision on the
Offering, including acceptance of the received bids, the number of Shares issued
and the subscription price of the Shares.  The final amount and subscription
price of issued Shares will be published after the close of the book-building
process.

The Shares are expected to be entered in the Finnish Trade Register
approximately on 26 April 2019, and trading of the Shares is expected to
commence on Nasdaq Helsinki Ltd approximately on 29 April 2019. The Shares will
rank pari passu in all respects with the existing shares of the Company once
they have been entered in the Finnish Trade Register.

In connection with the Offering, Revenio has entered into a lock-up undertaking,
under which it has, subject to certain exceptions, agreed not to issue or sell
any Shares in Revenio for a period of 180 days after the closing of the
Offering.

Carnegie Investment Bank AB and Danske Bank A/S, Finland Branch act as Lead
Managers and Bookrunners of the Offering.

Revenio Group Corporation

Board of Directors

Further information

Timo Hildén, CEO, Revenio, +358 40 580 4774, timo.hilden@revenio.fi
Robin Pulkkinen, CFO, Revenio, +358 50 505 9932, robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki Ltd
Main media
https://www.reveniogroup.fi

Revenio Group in brief
Revenio is a Finnish, globally operating health technology corporation whose
worldwide success is based on strongly patented intraocular pressure measurement
technology.

The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare
Medical Oy. Revenio’s core business is to develop and commercialize effective
and easily adopted devices to assist in the diagnostics of glaucoma and its
monitoring during treatment.

Revenio seeks vigorous growth in health technology. Revenio aims to develop even
more efficient and easily adopted methods for the early-stage detection of
diseases with significance for public health. The focus of Revenio's technology
is on the early detection of glaucoma, skin cancer and asthma, and the
monitoring of these during the treatment process.

In 2018, Revenio Group's net sales totalled EUR 30.7 million, with its net
operating profit standing at 33.3%. Revenio Group Corporation is listed on
Nasdaq Helsinki.

Disclaimer

Both Carnegie and Danske Bank are acting exclusively for the Company and no one
else and they will not regard any other person (whether or not a recipient of
this release) as their respective clients in relation to the Offering. Carnegie
and Danske Bank will not be responsible to anyone other than Revenio for
providing the protections afforded to their respective clients and will not give
advice in relation to the Offering or any transaction or arrangement referred to
herein. Carnegie and Danske Bank assume no responsibility for the accuracy,
completeness or verification of the information set forth in this release and,
accordingly, disclaim, to the fullest extent permitted by applicable law, any
and all liability which they may otherwise be found to have in respect of this
release. Nothing contained in this release is, or shall be relied upon as, a
promise or representation as to the past or the future.

The information contained herein is not for publication or distribution,
directly or indirectly, in or into the United States, Australia, Canada, New
Zealand, Singapore, Hong Kong, South Africa or Japan. This release does not
constitute an offer of securities for sale in the United States, nor may the
securities be offered or sold in the United States absent registration or an
exemption from registration as provided in the U.S. Securities Act of 1933, as
amended, and the rules and regulations thereunder. There is no intention to
register any portion of the Offering in the United States or to conduct a public
offering of securities in the United States.

The issue, exercise or sale of securities in the Offering are subject to
specific legal or regulatory restrictions in certain jurisdictions. Revenio
assumes no responsibility in the event there is a violation by any person of
such restrictions.

The information contained herein shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of the securities
referred to herein in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration, exemption from registration or
qualification under the securities laws of any such jurisdiction.

Revenio has not authorized any offer to the public of securities in any Member
State of the European Economic Area. The securities referred to in this release
may only be offered in Relevant Member States (a) to any legal entity which is a
qualified investor as defined in the Prospectus Directive; or (b) in any other
circumstances falling within Article 3(2) of the Prospectus Directive. For the
purposes of this paragraph, the expression ”Prospectus Directive“ means
Directive 2003/71/EC (and amendments thereto).

This communication is directed only at (i) persons who are outside the United
Kingdom or (ii) persons who have professional experience in matters relating to
investments falling within Article 19(5) of the Financial Services and Markets
Act 2000 (Financial Promotion) Order 2005 (the “Order”) and (iii) high net worth
entities, and other persons to whom it may lawfully be communicated, falling
within Article 49(2) of the Order (all such persons together being referred to
as “relevant persons”). Any investment activity to which this communication
relates will only be available to and will only be engaged with relevant
persons. Any person who is not a relevant person should not act or rely on this
document or any of its contents.